Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이은경 | * |
dc.date.accessioned | 2016-08-29T12:08:10Z | - |
dc.date.available | 2016-08-29T12:08:10Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 1492-2918 | * |
dc.identifier.other | OAK-15051 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/230608 | - |
dc.description.abstract | Purpose To compare the stability, effectiveness, and safety profiles of a new generic sevoflurane with those of the original sevoflurane formulation in patients undergoing elective surgery. Methods An accelerated 3-month storage test was performed to evaluate the compositional changes in generic sevoflurane stored in glass bottles. In addition, 182 patients were randomly allocated to receive generic (n = 89 [54 men and 35 women]; mean [SD] age, 49.9 [11.6] years) or original (n = 93 [61 men and 32 women]; mean [SD] age, 49.6 [11.1] years) sevoflurane at a gas flow of 3 L/min for approximately 3 hours. The mean minimum alveolar concentration (MAC) during sevoflurane anesthesia was evaluated, and gas samples for measuring compound A were collected from the inspiratory limb of the circuit at preset intervals. Blood samples for measuring serum inorganic fluoride were obtained at preset intervals (pharmacokinetic group: generic/original sevoflurane = 45/46). Renal biomarkers, such as N-acetyl-β-glucosaminidase, α- and π-glutathione-S-transferase, albumin, urine protein and osmolality, serum creatinine and osmolality, creatinine clearance, and blood urea nitrogen, were measured at preset intervals (renal biomarker group: generic/original sevoflurane = 44/47). Adverse reactions were monitored for 72 hours after discontinuation of sevoflurane use. Findings Generic sevoflurane contained in glass bottles was stable for 3 months. The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%). Adverse event rates were similar (90.3% vs 84.3%), as were the AUC<inf>last</inf> of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm). Biomarkers associated with renal injury were not significantly different between the 2 formulations. Implications No significant difference was found in the mean MAC between generic and original sevoflurane. ClinicalTrials.gov identifier: NCT01096212. © 2015 Elsevier HS Journals, Inc. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Excerpta Medica Inc. | * |
dc.subject | compound A | * |
dc.subject | effectiveness | * |
dc.subject | generic sevoflurane | * |
dc.subject | inorganic fluoride | * |
dc.title | An Open-label Comparison of a New Generic Sevoflurane Formulation with Original Sevoflurane in Patients Scheduled for Elective Surgery under General Anesthesia | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 37 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 887 | * |
dc.relation.lastpage | 901 | * |
dc.relation.journaltitle | Clinical Therapeutics | * |
dc.identifier.doi | 10.1016/j.clinthera.2015.01.012 | * |
dc.identifier.wosid | WOS:000354421100020 | * |
dc.identifier.scopusid | 2-s2.0-84940005194 | * |
dc.author.google | Byon H.-J. | * |
dc.author.google | Choi B.-M. | * |
dc.author.google | Bang J.-Y. | * |
dc.author.google | Lee E.-K. | * |
dc.author.google | Lee S.-S. | * |
dc.author.google | Noh G.-J. | * |
dc.contributor.scopusid | 이은경(57188770360;57217075385) | * |
dc.date.modifydate | 20240123125059 | * |